^
Association details:
| Biomarker: | EGFR N771_P772insH |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ivesa (furmonertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review
Published date:
08/17/2022
Excerpt:
...we report the case of a 57-year-old man with advanced non-small cell lung cancer (NSCLC) with a rare EGFR exon 20 N771_P772insH mutation. The patient was treated with furmonertinib as second-line therapy….The patient was evaluated for a remarkable progression-free survival (PFS) of 10.0 months, a duration of response (DOR) of 8.0 months, and an overall survival (OS) of 22.0 months, which had not previously been achieved.
DOI:
https://doi.org/10.3389/fphar.2022.964606
